Lack of efficacy (protozoa) - Ehrlichia

Verify with FDA CVM →

VeDDRA Code: 2805

251 adverse event reports referencing this reaction

251
Total Reports
3
Deaths
120.0%
Death Rate

Species Most Affected

Dog 251

Breeds Most Affected

Retriever - Labrador 41
Crossbred Canine/dog 26
Retriever - Golden 18
Dog (unknown) 18
Shepherd Dog - German 17
Terrier (unspecified) 10
Hound (unspecified) 8
Beagle 8
Shih Tzu 6
Shepherd Dog - Australian 6

Associated Drugs

Afoxolaner 91
Fluralaner 13.64% 12-Week Chew 56
Pyrantel Pamoate;Sarolaner 47
Sarolaner 39
Lotilaner 23
Ivermectin + Pyrantel As Pamoate Salt 8
Milbemycin Oxime + Praziquantel 7
Selamectin 3
Fluralaner Chew Tablets 2
Doxycycline 2
Recombinant E. Coli Bl21;Recombinant E. Coli Ecl19 2
Milbemycin/Praziquantel 2
Borrelia Burgdorferi Bacterin 1
Leptospira-Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract 1
Milbemycin/Lufenuron Tablets 1
Lyme Vaccine 1
Fipronil + Permethrin + Pyriproxifen 1
Glucosamine 1
Moxidectin 1
Ivermectin + Pyrantel 1

Data Summary

Metric Value
Total reports referencing reaction 251
Reports with fatal outcome 3
Case-fatality rate (reported events) 120.0%
Species observed 1
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2805.

Lack of efficacy (protozoa) - Ehrlichia Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 251 adverse event reports that reference Lack of efficacy (protozoa) - Ehrlichia as a reaction term, including 3 reports with a death outcome — a 120.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2805, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Lack of efficacy (protozoa) - Ehrlichia appears most frequently in reports for Dog (251 reports) — with Dog dominating at 251 entries. Within those species, the breeds most often named alongside this reaction are Retriever - Labrador (41), Crossbred Canine/dog (26), Retriever - Golden (18). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Lack of efficacy (protozoa) - Ehrlichia are Afoxolaner (91 reports), Fluralaner 13.64% 12-Week Chew (56 reports), Pyrantel Pamoate;Sarolaner (47 reports), Sarolaner (39 reports), with Afoxolaner appearing alongside this reaction in 91 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial